As early as 2017, some studies highlighted that HF-rTMS could be used to improve functional recovery in patients with ischemic stroke by enhancing neurogenesis and activating brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB) signaling pathways (100). This evidence concerns the gene BDNF and ischemic stroke.